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Abstract:
Calmodulin antagonists have been shown to enhance DNA damage
induced by a variety of chemical and physical agents, including 254
nanometer (nm) ultraviolet (UV) light in normal human fibroblasts. These
studies have suggested the existence of a calmodulin mediated process of
DNA repair that is a potential target for the development of new
therapeutic approaches for neoplastic diseases We examined the
interaction of calmodulin antagonists and UV irradiation against murine
lymphoblastic leukemia (LI210) and human T-cell lymphoblastic leukemia
(CEM) cell lines.
Cells were grown in suspension culture and were exposed to 10 J/m2 of
254 nm UV light in sterile vessels. Exposure was followed by incubation
with varying concentrations of the calmodulin inhibitors trifluoperazine or
melittin . Cells were counted daily and degree of inhibition of cellular
proliferation was examined. Dose response relationships for LI210 and
CEM cells were established for the calmodulin antagonists and UV exposure
using measurements of cellular proliferation.
Our results demonstrated that recovery from UV irradiation was not
significantly inhibited in the presence of calmodulin antagonists in either
of the cell lines studied, implying that calmodulin is not involved in the
repair of UV induced pyrimidine dimers.

*

2

Introduction:
In recent years the existence of a calcium messenger system as a
fundamental means of regulating cellular functions has been well
established. The large gradient between extracellular Ca++ concentrations
(~1mM) and intracellular free calcium concentration (-100-200 nanomolar)
is maintained by a complex series of homeostatic mechanisms. Small
changes in intracellular calcium concentrations affect a wide variety of
cellular functions as part of a “second messenger" system analagous to the
cyclic adenosine 3‘,5’-monophosphate (cAMP) messenger system. A small
protein, calmodulin, plays an important role in the calcium messenger
system.1
Calmodulin was discovered in the late 1960s and has been discussed
extensively in many review articles in recent years.3 A5A7A9 it is a
small (148 amino acid, molecular weight 16,700), acidic, heat stable
protein present in all eukaryotic cells examined to date. It has been highly
conserved across evolutionary lines, and only subtle differences have been
identified in the sequences of calmodulins purified from species which are
widely separated phylogenetically, a factor which implies that calmodulin
is part of a regulatory system common to all eukaryotic cells.
Each molecule of calmodulin has four structurally similar domains,
each of which can bind a single Ca++ ion in response to changes in the
intracellular calcium concentration. The binding of Ca++ to calmodulin
produces conformational changes, which allow the specific interaction of
calmodulin with a number of target proteins. Activity of the target proteins
may be altered in this manner, causing changes in a variey of cellular
functions.
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Strict criteria for the designation of calmodulin-dependent processes
have been set forth by Cheung, one of the first to describe the protein.10
Enzymes which have met the stringent criteria include ones involved in
cyclic nucleotide metabolism1

\ protein phosphorylation12, energy

metabolism13 and other key cellular functions. The list of processes in
which calmodulin has been implicated as a regulator is much longer, and
includes such processes as DNA synthesis14, cell growth and
differentiation15, and mictrotubular function16 which are important in
consideration of the role calmodulin may play in neoplastic cells.
A large number of compounds have been demonstrated to be
calmodulin antagonists. (For reviews, see 17,18,19) jne phenothiazine
family of compounds, used clinically as anti-psychotics, were the first
compounds to be used experimentally as calmodulin inhibitors. A wide
variety of compounds from different structural classes have subsequently
been shown to have calmodulin antagonist activity, including the
napthalenesulfonamide, or “W" compunds. Known calmodulin antagonists,
however, suffer from a lack of specificity, and are known to exert effects
on cellular components such as membranes and hormone receptors which are
not directly linked to their effects as calmodulin antagonists. This
complicates their use as tools for the elucidation of calmodulin-dependent
processes. Structure-activity analysis of calmodulin inhibitors by
Prozialeck and Weiss have defined the essential stuctural features for
calmodulin antagonism to include a large hydrophobic region composed of at
least two aromatic rings and an amino group separated from the hydrophobic
region by a side chain of at least four atoms.20
The large amount of research which examines the role of calmodulin
in neoplasia has been discussed in several reviews.15,2! ,22,23 Hait and
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Lazo have summarized a large number of investigations in which calmodulin
antagonists have been shown to inhibit cell growth and induce
cytotoxicity.23 Most experiments have involved work with malignant cell
lines in culture, although some in vivo animal experiments have been
reported and clinical trials are currently in progress. Many of the studies
summarized demonstrated a good correlation between the concentration of
calmodulin inhibitors required to inhibit clonogenicity and the concentration
required to inhibit calmodulin in cell free assay systems.
Several lines of research address the role which calmodulin may
play in neoplastic cells. Increased concentrations of calmodulin have been
reported in some, but not all studies in which the calmodulin content of
hyperproliferative and malignantly transformed cells has been compared to
that in controls.15 Cell-cycle specific elevations in calmodulin content have
been reported, and progression through the cell cycle has been shown to be
inhibited by calmodulin antagonists.24-25 However, the capacity of
calmodulin to alter protein activity by phosphorylation leaves open the
possibility that calmodulin may specifically affect neoplastic cells via the
regulation of as yet unidentified processes. As mentioned previously, data
implicates calmodulin as a regulator of many more processes than are
currently definitively categorized as calmodulin-dependent.
The following review attempts to summarize the data linking
calmodulin to the fundamental cellular process of DNA repair.
Experiments have been conducted using physical factors known to induce
DNA damage, such as ultraviolet (UV) light, x-irradiation, and
hyperthermia, in conjunction with calmodulin antagonists. In addition,
many chemotherapeutic agents currently in use are thought to exert their
therapeutic effects by inducing DNA damage, and experiments have been

-
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performed which examine their interactions with calmodulin antagonists.
The potentiation of therapeutic effects produced by DNA damage in
malignant cells may be mediated by the inhibition of DNA repair processes.
Thus, the findings that calmodulin antagonists may be regulators of DNA
repair indicate that there may be a role for calmodulin antagonists as
components of new regimens in anti-neoplastic therapy.
Using Chinese hamster ovary (CHO) cells growing exponentially in
culture, Chafouleas, Bolton, and Means examined the effects of members
of the napthalenesulfonamide class of calmodulin inhibitors in combnation
with bleomycin. 26 Bleomycin, an anti-tumor antibiotic, is thought to act
by fragmenting DNA. The authors noted that when CHO cells were treated
with non-toxic concentrations of bleomycin in combination with non-toxic
concentrations of the calmodulin inhibitor W-13, a dramatic decrease in
the fraction of surviving cells was noted. There was a dose-dependent
decrease in the surviving fraction of cells as the concentration of W-13
was increased. This effect was not noted when compound W-12 , an analog
of W-13 which is not active as a calmodulin antagonist, was used. The
combination of W-12 and bleomycin did not cause greater cytotoxicity
than did bleomycin alone. Inhibition of recovery from bleomycin induced
potentially lethal damage was also noted with trifluoperazine.
As they noted these effects with calmodulin Inhibitors from two
different structural classes, the authors postulated that their results
were due to the inhibition of a calmodulin dependent DNA repair process.
They noted a decrease in the nucleoid sedimentation migration rate, a
measure which has been shown to correlate with DNA damage, in nucleoids
which had been prepared from cells treated with bleomycin. In cells
allowed to recover after exposure to bleomycin in either fresh medium or

-
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medium to which the inactive calmodulin inhibitor W-12 was added,
recovery of the nucleoid sedimentation ratios to control levels were noted.
However, when the cells were treated with the calmodulin inhibitor
W-13 after exposure to bleomycin, the nucleoid sedimentation migration
ratio was much lower than that of the control, at a level approximately
that of the cells treated with bleomycin alone, without the oppurtunity for
recovery. The authors concluded that DNA repair had not taken place in
presence of the calmodulin antagonist W-13, but had occured when the
inactive congener W-12 was present.
Chafouleas and his colleagues also performed experiments on E.
Coli.26 Unlike eukaryotes, E. Coli has not been shown to contain
calmodulin. The authors found that W-13 did not potentiate DNA damage
induced by bleomycin in this experimental system, providing additional
support for their contention that the observed potentiation of bleomycin
induced cytotoxicity was due to the inhibition of calmodulin
Lazo, Hait and their colleagues also studied the effects of calmodulin
antagoinsts in combination with bleomycin, using other experimental
systems.27.28 Using L1210 murine leukemia cells, they demostrated
enhancement of cytotoxicity when calmodulin antagonists were
administered with bleomycin. These results were noted when calmodulin
antagonists from a variety of different structural classes, the
napthalenesulfonamide W-7, the phenothiazines trifluoperazine and
chlorpromazine, the diphenylbutylpiperidine pimozide, and the peptides
melittin and mastoporan, were used. The potentiation of bleomycin induced
cytotoxicity was not noted when the napthalenesulfonamide W-5 and the
phenothiazine chlorpromazine sulfoxide, which are not active as
calmodulin antagonists, were used.

.
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Lazo and his associates further characterized the interaction of
calmodulin inhibitors and bleomycin with human 5K-OV ovarian carcinoma
cells, A-253 head and neck squamous carcinoma cells, and human
hematologic stem cell colonies.29 The authors demonstrated a dose
dependent enhancement of bleomycin induced cytoxicity in the 5K-0V and
bone marrow progenitor cells using the calmodulin inhibitors
chlorpromazine, melittin, and pimozide. However, they noted no such
enhancement in the A-253 cell line, with is more sensitive to bleomycin
than the other cell lines studied.
In addition to noting the enhancement of cytotoxicity, Lazo, Hait and
co-workers directly examined the effects of bleomycin and calmodulin
antagonists on DNA.27 Using alkaline elution techniques to examine DNA
from the LI210 cells, the authors noted an incresed number of DNA breaks
in cells treated with bleomycin in conjunction with pimozide when
compared to cells treated with bleomycin alone. DNA from cells treated
with pimozide alone did not have an increased numer of breaks when
compared to DNA from untreated cells. In a cell-free system using
plasmid DNA, the authors noted no potentiation of bleomycin induced DNA
breakage with the addition of pimozide.
Lazo, Hait, et. al. concluded that the calmodulin antagonist mediated
augmentation of bleomycin induced cytotoxicity was secondary to
increased damage to the cellular DNA. This increased damage could have
been a direct effect of the combination, or an indirect effect mediated by
inhibition of DNA repair mediated by inhibition of calmodulin, as suggested
by Chafouleas, Bolton, and Means.26 Although the concentrations of
calmodulin antagonists required to enhance cytotoxicity are similar to the
concentrations required to inhibit calmodulin, the lack of specificity of

-
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currently utilized calmodulin antagonists makes it difficult to
definitively define the role of calmodulin in these processes.29
Nonetheless, the observed potentiation of bleomycin induced DNA damage
is clearly consistent with inhibition of DNA repair mechanisms by
calmodulin antagonists.
Based on the observed in vitro potentiation of bleomycin induced
cytotoxicity by calmodulin antagonists, a Phase HI study using
trifluoperazine in combination with bleomycin was conducted. Patients
with a variety of malignancies, including Mycosis Fungiodes and
gynecologic malignancies, were enrolled in the study. Although
neuropsychiatric side effects and other toxicities were noted, several
patients had measurable responses to the experimental regimen, and
further clinical evaluation seems merited.30
In an attempt to further examine the hypothesis that calmodulin
antagonists inhibited DNA repair processes, Lazo, Hait et.al. also treated
cells with calmodulin antagonists in combination with other agents known
to cause repairable DNA damage. Using calmodulin antagonists in
combination with x-irradiation and the chemotherapeutic agent etoposide,
the authors were unable to demonstrate cytotoxic augmentation in LI210
cells.27
The absence of a synergistic effect between calmodulin antagonists
and X-irradiation was subsequently demonstrated by Ridinger and his
colleagues in experiments utilizing a murine mammary carcinoma cell line.
The investigators found that addition of the calmodulin inhibitor W-13 to
cell cultures prior to X-irradiation had no effect either on cell survival,
the amount of DNA damage induced, or the ability of the cells to repair the
X-ray induced DNA damage.31

.
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George and Singh, however, noted different effects in in vivo
exDeriments using x-rays In combination with calmodulin antagonists.
Using a transplantable murine fibrosarcoma, they found

that the

phenothiazines promethazine, prochlorperazine, and trimeprazlne did not
delay tumor growth. However, when the same compounds were
administered to mice prior to x-ray treatments, potentiation of
growth delay produced by x-irradiation alone was
The

the tumor

noted,32

potential use of hyperthermia in cancer therapy has attracted

Increased attention in recent years, as the increased sensitivity of tumor
cells over that of normal cells has become recognized. Hyperthermia has
multiple effects on the cell, including effects on DNA synthesis

and

replication.33 Specific effects on DNA repair have been suggested by
Corry et. al., who noted potentiation of cytotoxicity, as well as inhibition
of DNA repair mechanisms, in CHO cells treated with hyperthermia

in

combination with ionizing radiation.34 Later work by Meyn, Corry and
colleagues showed that treatment of CHO cells with bleomycin at 43 *C
caused significantly greater cytotoxicity than treatment with identical
concentrations of drug at 37 ’C 35 Alkaline elution analysis revealed that
the enhancement of cytotoxlcty at the higher temperature was not
explicable by an increase in the degree of DNA breakage. Instead, the
authors demonstrated that the DNA repair of bleomycin induced DNA
damage was rendered less effective by hyperthermia
Using Reuber H35 rat hepatoma cells and N3A neuroblastoma cells,
Wlegant and his colleagues demonstrated significant potentiation of
hyperthermic cytotoxicity when cells were simultaneously treated with
trifluoperazine.36 Concentrations of trifluoperazine (5um and 10pm)
were used which had been shown to be noncytotoxic alone. With the

■
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concurrent administration of hyperthermia (43° C for 1 hour) however, the
same doses of trifluoperazine were found to produce cytotoxic
enhancement Similar results were obtained for both the neuroblastoma
and hepatoma cell lines. In vivo studies by George and Singh found that
treatment of a transplantable murine fibrosarcoma with non-toxic doses
chlorpromazine prior to treatment with hyperthermia delayed tumor
growth to a greater degree than did hyperthermia alone.37
Given that interactions of bleomycin and hyperthermia, hyperthermia
and calmodulin antagonists, and bleomycin and calmodulin antagonists
have all been shown to effect enhanced cytotoxicity, it is not suprising
that combinations of all three agents have shown further enhancement.
Smith, Mircheva. and Bleehen, using murine EMT6 mammary tumor cells,
investigated the combination of bleomycin, hyperthermia (44 °C) and
trifluoperazine. 38,39,40 setting the degree of cytotoxicity (as measured
by clonogenicity) produced by bleomycin alone as 1.0, they found that the
addition of a non-toxic dose of trifluoperazine alone enhanced the degree
of cytotoxicity by a factor of 1.3 while the addition of a non-toxic
exposure of hyperthermia enhanced by a factor of 19. The combination of
the exposures of bleomycin with trifluoperazine and hyperthermia
produced enhancement by a factor of 112, a greater than additive effect.
Unfortunately, the authors did not present data showing the effect of
hyperthermia and trifluoperazine in combination without concurrent
bleomycin administration.
Smith, Mircheva, and Bleehan examined the DNA damage caused by
these therapeutic combinations by using both the nucleoid sedimentation
and alkaline denaturatlon assays. The nucleoid sedimentation assay
preferentially detects single strand breaks in DNA, whereas the alkaline
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denaturation assay detects both phosphodiester bond breaks in the DNA as
well as alkali labile lesions. The alkali labile lesions are
apyrimidinic/apurinic sites (AP sites) where bases are missing from the
DNA molecule without frank breaks of the DNA strand. Analysis of results
from the two different assays of DNA damage showed that while
hyperthermia diminished the repair of bleomycin induced DNA damage by
depressing the repair of both single-strand breaks (ssbs) and AP sites,
trifluoperazine selectively interfered with the repair of AP sites. As the
calmodulin antagonist trifluoperazine and hyperthermia appear to inhibit
the repair of DNA damage by separate mechanisms, the potential for a
synergistic enhancement of the cytotoxic effect of bleomycin is
established.
Charp and Regan examined the effects of the calmodulin inhibitor
trifluoperazine in combination with 254 nm UV light on normal human skin
fibroblasts in culture.41 Having prelabeled the cells with 3H thymidine,
20 Joules/meter2 (J/m2) of 254 nm UV light was administered to initiate
the formation of cyclobutane pyrimidine dimers. Immediately after UV
exposure, either 25pM of trifluoperazine or a control solution was added,
and the percentage of pyrimidine dimers remaining was followed by twodimensional paper chromatographic analysis of hydrolyzed DNA from the
exposed fibroblasts.
After 24 hours of post-exposure Incubation, the authors noted that 73%
of the pyrimidine dimers remained in the cells treated with
trifluoperazine as compared to 53.5% remaining in the cells treated with
control solution only after UV exposure. This 26% difference was
significant, however, no significant difference was noted In the DNA
prepared from ceils either 3 or i 2 hours post-exposure.

'
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The authors tried to determine which step of the DNA repair process
was affected by trifluoperazine by examining its effects with other assay
systems for DNA repair. Using bromodeoxyuridine photolysis, normal
function of exonuclease and polymerase activity was demonstrated in the
presence of trifluoroperazine. These results led the authors to conclude
that calmodulin antagonists specifically acted upon the incision step of
repair. Additional data obtained by inhibiting polymerase activity with
cytosine-arabinoside supported this conclusion.
Kwok and Twentyman examined the effects of a number of cytotoxic
chemotherapeutic agents in combination with trifluoperazine.42 They used
small spheroids of murine EMT6/Ca/VJAC mammary tumor cells treated
with bleomycin, CCNU, nitrogen mustard, and x-irradiation and exposed to
non-toxic concentrations of trifluoperazine for 24 hours after exposure to
the cytotoxic agents. No difference was noted in the surviving fraction of
these cells after the 24 hour exposure to trifluoperazine when compared
to the surving fraction measured immediately after exposure to the
cytotoxic agent, without exposure to the calmodulin antagonist. The
authors were unable to demostrate an effect of calmodulin antagonists on
recovery from potentially lethal DNA damage in the experimental system
used.
Darkin and his colleagues found that DNA isolated from PY815 cell
nuclei was damaged after treatment with the DNA intercalating agent mAM5A 43 The DNA was resealed when the nuclei underwent subsequent
incubation in drug-free medium. However, the degree of repair was
significantly inhibited when incubation took place in the presence of
chlorpromazlne, Indicating that the DNA repair may have been calmodulin
mediated.

,
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Interactions between doxorubicin and related anthracycline
compounds, compounds felt to work by intercalation into and disruption of
nucleic acids, with calmodulin antagonists have been explored by
Ganapathi and his associates.44*45 Much of their work has involved the use
of a doxorubicin-resistant P388/DOX murine leukemia line, where they
have demonstrated up to a TOO fold increase in anthracycline induced
cytotoxicity with the use of trifluoperazine. The mechanisms underlying
the resistance of these cells to doxorubicin and other compounds are
unclear, as is the entire phenomenon of multidrug resistance (For a recent
review, see 46). Cytotoxic enhancement was also noted in experiments
with the non-resistant P388/5 cell line. These results were dosedependent, and were noted with both trifluoperazine and chlorpromazine at
concentrations appropriate to the potency of the two compounds as
calmodulin antagonists 44
In further experiments with the non-resistant P388/5 cell line,
Ganapathi and his associates noted that calmodulin antagonists
preferentially enhanced the cytotoxicity of strong DNA binding agents,
including the chemotherapeutic agents dactinomycin and AM5A, in addition
to the anthracyclines doxorubicin and daunorubicin.47 In contrast, they
did not note enhancement of cytotoxicity when weakly DNA binding
anthracycline analogs were used. The mechanism of cytotoxic
enhancement in the sensitve P388/5 cell line is less well understood than
in the resistant phenotype, where attention has been focused on
differences in cellular uptake and retention of the anthracyclines.44*45
However, the existence of cytotoxic enhancement of strong DNA binding
agents from a variety of different structural classes by calmodulin

■
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antagonists indicates that calmodulin may be involved as a regulator of
the DNA damage and repair mechanisms involved.
The studies linking agents which can induce DNA damage and
calmodulin antagonists discussed above, are summarized below in Table 1.
To expand the exploration and characterization of the effects calmodulin
antagonists may have in combination with DNA damaging agents, we were
interested in exploring their effects in combination with 254 nm UV light
in malignant cell lines. The existence of synergism or augmentation of UV
induced cytotoxicity by calmodulin antagonists would strengthen the case
for the role of calmodulin as a mediator of DNA repair processes.
The cyclobutane dimer formed by adjacent pyrimidine bases in DNA
upon absorbtion of UV light in the 254 nm range is a well understood model
of DNA damage, and has been described as the "classic test lesion" for the
study of DNA repair.48 Once formed, the dimers block DNA replication and
can result in cell death. Repair of damage involves the recognition of
abnormality, the excision of the affected bases, usually along with
adjacent nucleotides, and the replacement of the segment of DNA removed,
using the complementary strand as a template. Deficiency in this repair
mechanism, as occurs in the human disease Xeroderma Pigmentosa, results
in increased incidence of cancer. Experimental work in E.Coli. has shown
that even a single unrepaired dimer may prove lethal.48 As UV induced DNA
damage and repair is especially well understood, work done with this
experimental system stands a greater chance of allowing insights into the
specific site in the DNA repair process at which calmodulin antagonists
are effective.

'
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Table 1: Summary of studies using calmodulin antagonists In
combination with physical and chemical agents which damage DNA
DNA-dam aging
agent

Experimental
System

Calmodulin
Antagonist

Result

Bleomycin

CHO cells

W-13, TFP

26

L1210 cells

Plasmid DNA

W-7.TFP,
CPZ, PIM,
Mel, Mas
PIM

Enhancement
noted
Enhancement
noted

27

SK-OV cells

CPZ,PIM,Mel

A-253 cells

CPZ, PIM, Mel

No Enhancement
noted
Enhancement
noted
No Enhancement
noted
Enhancement
noted
No enhancement
noted
Enhancement
noted
No Enhancement
noted
No Enhancement
noted
No Enhancement
noted
Enhancement
noted

31

Bone marrow
CPZ, PIM, Mel
progenitor cells
EMT.6 cell
TFP
spheroids
EMT6 cells
TFP

X-irradiation

67 (P) cells

W-13

L1210

PIM, Mel

EMT6 cell
spheroids
in vivo murine
fibrosarcoma

TFP
PMZ, PPZ, TPZ

Reference

27,28

29
29
29
42
38,39

27
42
32

Hyperthermia Neuroblastoma
N3A cells, H35
hepatoma cells
In vivo murine
fibrosarcoma

TFP,
Calmidazolium

Enhancement
noted

36

CPZ

Enhancement
noted

37

Bleomycin & EMT6 cells
Hyperthermia

TFP

Enhancement
noted

38,39
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Table 1 (continued):
DMA-dam aging
agent

Experimental
System

Calmodulin
Antagonist

Result

Ultraviolet
light
(254 nm)

Normal human
fibroblasts
L1210 cells

TFP

CEM cells

TFP

41
Enhancement
noted
No Enhancement *
noted
No Enhancement *
noted

AMSA

Doxorubicin

TFP, Mel

PY815 cell nuclei CPZ
P388/S cells

TFP

P388/5 cells

TFP

EMT6 cell
spheroids

TFP

Reference

Enhancement
noted
Enhancement
noted

43
47

47
Enhancement
noted
No enhancement 42
noted

Dactinomycin P388/S cells

TFP

Enhancement
noted

47

CCNU

EMT6 cell
spheroids

TFP

No Enhancement
noted

42

Nitrogen
Mustard

EMT6 cell
spheroids

TFP

No Enhancement 42
noted

Etoposide

L1210 cells

PIM, Mel

No Enhancement
noted

27

*5ee Results section of this document.
Abbreviations: TFP-Trlfluoperazine; CPZ-Chlorpromazine; PIM-Pimozide;
Mel-Melittin; Mas-Mastoporan; PMZ-Promethazine; PPZ-Prochlorperazine;
TPZ-Trimeprazine.

/
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Materials and Methods:
Cells:
LI210 murine leukemia cells were maintained in suspension culture in
Fisher's medium with 10% horse serum.

CEM human lymphoblastic

leukemia cells were maintained in suspension culture in RPMI medium
with penicillin, streptomycin, and 10% horse serum. All cultures were
stored in a 5% CO2 atmosphere in an incubator at 37' C. Cultures were
passed at least twice weekly.
Ultraviolet (UV) Light:
UV exposure was provided by a Spectronics XX15A UV lamp containing a
single BLE IT 155 254 nm. bulb. UV exposure was quantitated using a
Schlumberger UV light meter and found to be approximately 10 J/m2 in 15
seconds at the 70 cm. exposure distance utilized.
Drugs:
Trifluoperazine hydrochloride and melittin were obtained from the
Sigma Chemical Co. (5t. Louis). Drug solutions were prepared no earlier
than the day prior to the experiment using distilled H2O which had been
sterilized by passage through 0.22um filter. Solutions were shielded from
light and stored in the refrigirator.
Studies of Cellular Proliferation:
Cells growing in log phase were pipetted from culture flasks at an
initial concentration of approximately 50,000/ml. Cells were placed in
Petri Dishes or Nunc Plates at a depth of 0.25 cm. and exposed to UV light
from a height of 70 cm.. During exposure, cells were placed on a Tektator
rotating shelf at 60 r.p.m.

M-
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Drugs were added within 1 hour after UV exposure. Cells counts were
made initially within 2 hours of exposure and daily thereafter using a
Coulter Counter.
Figures:
Figures were prepared on a Macintosh computer using the Cricket Graph
software package (Cricket Software, Philadelphia). On those figures
which include error bars, error bars are not included for those points
where the error is smaller than the marker for the data point. Growth
curves included with the figures were plotted using the exponential
regression fit feature of Cricket Graph.

■
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Results:
Figure 1 shows the response to LI210 cells to different lengths of
exposure to 254 nm UV light. Each data point represents the mean of two
replicates. The graphs demonstrate an exposure dependent relationship with
increasing duration of exposure to UV.
Figure 2 shows the response of LI210 cells to incubation with
differing concentrations of trifluoperazine. Each data point represents the
mean of two replicates. The graphs demonstrate that for doses of 1 pm,
2pm, and 4pm, proliferation is not significantly inhibited, but that greater
than 50% inhibition is noted with a dose of 8pm.
Figure 3 shows the response of LI210 cells to differing
concentrations of melittin. Each data point represents the mean of four
replicates. These results demonstrated that melittin produced dose
dependent inhibition of cell growth, with a dose of 0.25pm of melittin
producing 45% inhibition when compared with the growth of control cells
after 48 and 72 hours of incubation.
This data allowed dose-response relationships for LI210 cells to the
agents under consideration to be established. Using this information, a 15
second exposure to UV, corresponding to a dose of 10 J/m2> was chosen.
This dose produced consistently reduced cell growth of UV treated cells to
approximately two-thirds the growth of control cells.
Cells were incubated with varying concentrations of melittin and
trifluoperazine after 10J/m2 UV exposure. Figures 4 and 5 show the growth
curves for the LI210 cells treated with UV and post-exposure incubation
with 2pm and 4pm concentrations of trifluoperazine, respectively. Each
data point represents the mean of four replicates. The results show that

.
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the combination of trifluoperazine and UV exposure caused no greater
reduction of cellular proliferation than did UV alone.
Figures 6,7, and 8 show similar curves for LI210 cells treated with
0.10pm, 0.25pm, and 0.50pm doses of melittin. Each data point represents
the mean of four replicates. The figures show that the combination of
treatment with UV and melittin had no greater effect on cellular
proliferation than UV alone. In fact, at doses of 0.25pm and 0.50pm of
melittin in combination with UV exposure, cells treated with both
modalities had greater growth than that of controls, indicating a possible
protective, rather than enhancing, effect of melittin in combination with
UV induced DNA damage.
The results of the combination of UV exposure and the calmodulin
inhibitors trifluoperazine and melittin at 48 hours after UV exposure are
summarized in Table 2.

Table 2: Effects of Calmodulin Antagonists and 254 nm UV
exposure on L1210 cell growth
Drug and
Concentration

No UV exposure
± 2 s.d.

With UV exposure % of Control growth
in UV treated cells
+ 2 s.d.

No Drug
2pm TFP
4pm TFP
0.10pm Mel
0.25pm Mel
0.50pm Mel

100.0+10.9
98.9+ 2.9
115.6 ±10.2
71.0+ 5.9
60.1 t 7.2
43.8 ± 5.0

68.5 +
88.2 +
75.4 +
55.3 +
65.2 +
46.8 ±

4.6
3.3
7.9
5.2
5.2
7.0

69
89
65
78
108
107

Results are expressed as increase over initial counts at 48 hours as a percentage of the increase
of cells not exposed to either drugs or UV.

CEM cells have a longer doubling time (approximately 24 hours) than
L1210 cells (doubling time 10 to 12 hours) and this is reflected in the
growth curves for the experiments with CEM cells. Figure 9 shows the
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effect of exposure to varying doses of UV light on the growth of CEM cells.
The results demonstrate that the sensitivity of CEM cells to 254 nm UV
light was similar to that observed with the LI210 cells, and accordingly
the same 15 second length of exposure was chosen for subsequent
experiments with the CEM cells.
Figure 10 shows the effect of varying doses of trifluoperazine on
the growth of CEM cells. The results show that for the CEM cells, incubation
with 2pm, 4pm, and 8pm concentrations of trifluoperazine did not produce
significant inhibition of growth, with a dose of 16pm producing
approximately 50% inhibition of growth. The CEM cells demonstrated the
same sharp increase in inhibition of cell growth near the IC50 as did the
LI210 cells, but the CEM cell line required considerably higher
concentrations of trifluoperazine for inhibition.
Figures 11 and 12 show the growth curves for the CEM cells treated
with UV in conjunction with 4pm and 8pm of trifluoperazine, respectively.
The higher concentrations of trifluoperazine used with the CEM cells
reflect the higher IC50 for trifluoperazine with the CEM cell line. Table 3
summarizes the results at 48 hours after UV exposure. The graphs and
Table 3 demonstrate that the no reduction in cell proliferation beyond the
degree of inhibition produced by UV exposure alone was produced by the
combination of UV and trifluoperazine.

-
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Table 3: Effects of Trifluoperazine and 254 nm UV light on CEM
cell growth
Drug and
Concentration

No UV exposure
+ 2 s.d.

With UV exposure % of Control growth
± 2 s.d.
in UV treated cells

No Drug
4jim TFP
8pm TFP

100.0 + 3.5
106.6 + 4.5
101.6+10.7

68.4+13.9
70.3 +13.5
72.5+14.5

68
66
71

Results are expressed as increase over initial counts at 48 hours as a percentage of the increase
of cells not exposed to either drugs or UV.
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Discussion:
We used the LI210 murine lymphoblastic leukemia and CEM human Tcell lymphoblastic leukemia cell lines in our studies. Both grow readily in
suspension culture. There has been extensive experience with the use of
L1210 cells, and their responses to trifluoperazine and melittin, the
calmodulin antagonists used in our studies, have been well characterized.
49,50 our results confirmed earlier findings with respect to the sensitivity
of LI210 cells to trifluoperazine and melittin, and established doseresponse relationships for CEM cells to trifluoperazine.
Many rodent cell lines are thought to be deficient in the repair of UV
induced pyrimidine dimers. However, mouse L cells have been shown to
excision repair mechanisms in place, although perhaps at reduced
levels.51.52 As we found that the human CEM cell line had similar
sensitivity to 254 nm UV light in our experiments, it is not probable that
this factor introduced a bias into our results. The effect of exposure to 254
nm UV light on proliferation of the LI210 and CEM cell lines in culture was
characterized.
In addition, use of the CEM line allows for more direct extrapolation
to the potential use of UV light in combination with calmodulin antagonists
for patients with human cutaneous T-cell lymphomas. Current treatments
for these diseases include the use of 8-methoxypsoralen (8-MOP). 8-MOP,
like the phenothiazines, is a photoactive tricyclic compound. It is thought to
act by intercalating into DNA, and forming photoadducts which can
covalently cross-link DNA when exposed to UV light in the ultraviolet A
(320-400 nm.) range.53 Oral 8-MOP has been used for many years for the
treatment of psoriasis and the plaque stage of cutaneous T-cell lympomas.
After oral administration, the drug becomes photoactivated by the exposure
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of cutaneous lesions to ultraviolet A. Recent work by Edelson and
associates has shown that extracorporeal UV and 8-MOP exposure of
affected lymphocytes from patients with disseminated cutaneous T-cell
lymphoma can be efficacious in patients whose lesions are not accessible to
cutaneous exposure. 54
The potential for calmodulin antagonists to have similar clinical
applications is possible. During their extended period of use as
psychotherapeutic agents, the phenothiazines have become known as
phototoxic compounds. Chlorpromazine and trifluoperazine, which have
absorbtion maxima at 308 nm and 313 nm, respectively, have been shown to
mediate these effects by both free radical and singlet molecular oxygen
formation.55 The photoactivation of these compounds by near UV (UV-A)
light has been shown to induce DNA damage in a number of experimental
systems 56<57>58>59 This body of research has been conducted with near UV
light however, while our experiments were conducted with far UV (UV-C)
light, which, unlike near UV radiation, produces DNA damage in the form of
pyrimidine dimers. Nonetheless, the potential existed that photoexcitation
of trifluoperazine could be produced by the higher energy UV source used in
our experiments. 254 nm UV exposure has been shown to induce covalent
bonding of trifluoperazine to calmodulin.17 Thus, to avoid cytotoxic
enhancement via a photochemical mechanism, we added phenothiazines to
the culture medium after, rather than during exposure to the UV light. Our
experiments did not examine a possible cytotoxic enhancement by a
photosensitization mechanism, but rather by a DNA damage and repair
mechanism.
Our results failed to demonstrate that calmodulin antagonists
enhanced the inhibition of cellular proliferation produced by short

■
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wavelength (254 nm) ultraviolet light in the LI210 and CEM cell lines
studied. These results do not confirm those earlier reported by Charp and
Regan, who had demonstrated enhancement of UV induced DNA damage in
normal human fibroblasts.41 The negative results obtained in our studies,
unfortunately, do not clarify the confusing, somewhat contradictory
literature which describes the interaction between calmodulin antagonists
and physical and chemical agents capable of damaging DNA. This literature
has been discussed in the introduction, and is summarized in Table 1.
This review of the literature revealed that while several authors had
not been able to demonstrate in vitro enhancement of X-irradiation induced
cytotoxicity, 27,31,42 others were able to demonstrate in vivo
enhancement.32 Multiple explanations are possible for these and the other
seemingly contradictory results which make up the literature in this area. It
has been demonstrated that the choice of different assay methods for
results may introduce bias.60 The fact that even with the same
investigators using the same techniques can obtain differing results with
different cell lines was demonstrated by Lazo and associates in their
studies on 5K-0V and A-253 cells.29 These differences in studies,
introduced by choices of different experimental systems and assay
techniques make it difficult to compare results.
Additional problems arise in quantifying the interactions noted
between biologically active agents. Although even a simply additive
enhancement of cytotoxicity or DNA damage may be significant, it is
important to distinguish the truly synergistic, greater than additive,
therapeutic combinations. Berenbaum has suggested isobologram analysis as
a means to distinguish between truly synergistic and simply additive

.
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effects 61, but most investigators do not subject their data to this means
of analysis.
Had our results demonstrated that calmodulin antagonists enhanced
UV induced cytotoxicity, further studies could have been performed. The
inhibition of cell growth measured in our studies could have been
supplemented with clonogenicity studies. These would have aided in the
differentiation between cells that were alive and not proliferating and cells
that had actually been killed.
Further studies would have been necessary to definitively attribute
the effects noted on cellular proliferation to inhibition of DNA repair
mechanisms. Other investigators have used serial measurements of the
degree of DNA damage, using techniques such as alkaline elution, in order to
assess DNA repair. Unfortunately, more precise techniques for the assay of
DNA repair inhibition are not easily available, and the measure of biological
end points is often used in the place of more specific assays.62
The lack of specificity of calmodulin antagonists would have made it
difficult to attribute positive results to the inhibition of calmodulin, as
known calmodulin antagonists have a variety of non-calmodulin mediated
pharmacologic effects. However, if similar results could have been
demonstrated with calmodulin antagonists as structurally distinct as
trifluoperazine and melittin at concentrations appropriate for calmodulin
inhibition, a strong case for the involvement of calmodulin could have been
made. Use of phenothiazines such as trifluoperazine oxide which are
inactive as calmodulin inhibitors could have served as additional controls.
Despite the negative results produced in our experimental system,
however, enough data has been presented in other studies to warrant
continued research to further delineate the role calmodulin and calmodulin

27

antagonists play in DNA damage and repair. Calmodulin antagonists such as
trifluoperazine are already in wide clinical use for psychiatric disorders
and have been demonstrated to be relatively well tolerated and non-toxic.
They have potential to be useful in anti-neoplastic therapy, and have already
begun to be used in combination with other agents in clinical trials.30
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